“我国中成药生产企业有2300多家，可生产的中成药仅4000余种，平均一家企业不到两个品种。这些企业生产的药品中，仿制、改制品种占有很高比例。”工业和信息化部消费品工业司医药处调研员张军在日前召开的中国泰州国际医药博览会上指出，尽管近两年，我国中药产业增长迅速，但我国中药产品缺少创新成为制约发展的瓶颈。

"Traditional Chinese medicine production enterprises in China more than 2300,It can produce more than 4000 kinds of Chinese only,Average company less than two varieties.The enterprise production of drugs,imitation/Restructuring of varieties of high proportion."Ministry of industry and information consumer goods industry company in medical investigator s held a few days ago China taizhou international medical fair points out,Although nearly two years,The rapid growth of Chinese materia medica industry,But China's traditional Chinese medicine products lack the innovation to become restrict development bottleneck.

　　我国医药工业2011年产值达1.452万亿元，其中中成药产值3300亿元，饮片870亿元。中药产业产值占总医药工业(含化药、生化药、中药等)产值的1/4强。而2012年前三季度，根据工业和信息化部统计，我国医药工业总产值1.288万亿元，同比增长20 .2%，其中中成药产值达3573亿元，同比增长17.9%；饮片产值922.3亿元，同比增长30 .8%。中药(含饮片)已占医药产业总产值的1/3。

China's pharmaceutical industry 2011 annual output value reached 1.452 trillion yuan,The traditional Chinese medicine the value of 330 billion yuan,Yinpian 87 billion yuan.Traditional Chinese medicine industry total output value of pharmaceutical industry(Including chemical drug/Biochemical medicine/Traditional Chinese medicine)A quarter of the value of strong.And the third quarter of 2012 years ago,According to the ministry of industry and information statistics,Our country medicine gross industrial output value is 1.288 trillion yuan,Year-on-year growth of 2%,The traditional Chinese medicine output value of RMB 357.3 billion yuan,Year-on-year growth of 17.9%;Prepared the value of 92.23 billion yuan,Year-on-year growth of 30. 8%.Chinese medicine(Prepared with)The pharmaceutical industry has accounted for a third of the total output value.

　　尽管中药产业取得了可喜的成绩，但创新是不可回避的短板。“中药不创新，将会陷入低水平重复的窘境，使价格成为影响产品市场发展的最重要手段，从而导致质量下降，损害消费者利益；中药不创新，将会被消费者放弃，在竞争中逐步出局；中药不创新，将永远无法进入国际主流药品市场。”国内一家知名中药企业的相关人士告诉记者。

Although Chinese medicine industry has made gratifying achievements,But innovation is unevadable short board."Not innovation of traditional Chinese medicine,Will be in low level repeated dilemma,The price be affect product market development is the most important means,Leading to the decline in the quality,Damage the interests of consumers;Not innovation of traditional Chinese medicine,Will be the consumer to give up,In the competition gradually out;Not innovation of traditional Chinese medicine,Will never enter the international mainstream medicine market."A domestic well-known traditional Chinese medicine enterprise relevant personage told reporters.

　　记者了解到，中药创新难主要有四方面的原因。

The reporter understands,The innovation of traditional Chinese medicine (TCM) there are four main aspects to reason.

　　一是虽然中医中药科研经历了很多年，但中药研究基础仍显薄弱。中药物质成分复杂，研究难度大、时间长，现代中药创新发展的规律性认识不足，这是最根本的原因。

One is although Chinese medicine scientific research experience for many years,But the research foundation of traditional Chinese medicine (TCM) still show weak.Traditional Chinese medicine composition complex,Research is difficult/Long time,Innovation and development of modern Chinese medicine regularity of lack of understanding,This is the most fundamental reason.

　　二是企业利润低，导致很多企业没有拿出金费进行研发。

The second is the enterprise profit is low,Lead to a lot of the enterprise did not take out money for research and development.

　　张军指出，药品降价、招标采购、市场竞争压力下，中药价格持续走低，企业利润受到挤压。而上游，中药材资源日益减少，随着国内消费需求与国际上对植物提取物需求的日益增长以及游资炒作，地道药材产量下滑等因素，导致中药材价格节节上涨，中药饮片加工业形势红火，而其下游的中成药企业的原料成本压力不断加大，赢利能力受到考验。

S pointed out that,Drug price/purchase/The market competition pressure,Traditional Chinese medicine prices keep falling,Corporate profits are squeezed.The upper and,Chinese herbal medicine resources are dwindling,Along with the domestic consumption demand and the international plant extracts growing demand and hot money speculation,Authentic materials production factors such as the decline,Lead to Chinese herbal medicine price rise successively,Chinese medicine yinpian processing industry is the situation,And the downstream proprietary Chinese medicine enterprise material cost pressure increasing,Profitability is tested.

　　三是创新药研发出来后，市场不支持。

Three is the innovative drug r&d after coming out,Market does not support.

　　“创新药进不了医保目录、进不了基本药物目录，企业都不知道创新药去哪里找出路。”中国医药企业管理协会会长于明德指出，国家政策大力支持创新药的研发，但是市场并不支持创新药的使用，导致“创新药只停留在实验室”的尴尬局面。

"Innovation medicine into the medical insurance directory/Can't get into the essential drugs list,Enterprise all don't know innovation medicine where to go to look for a way out."Chinese medicine enterprise management association YuMingDe pointed out,National policy support innovation medicine research and development,But the market does not support the use of innovative medicine,Lead to"Innovation medicine only stay in the laboratory"Awkward situation.

　　四是中药临床试验机构的研究水平与中药创新需求尚不相适应。

The fourth is traditional Chinese medicine clinical test institutions of traditional Chinese medicine research level and innovation demand is still does not adapt.

　　“标准化是中药创新的关键点。”康缘药业董事长萧伟认为，标准化是提升中药产品的安全性、有效性最为有效的手段。近两年，中药注射剂不良反应事件频频发生，其实从根本上说，并不是中药注射剂本身的问题，而是中药注射剂生产过程、原料过程中的控制和成品的质量标准有问题。

"Standardization is the key innovation of traditional Chinese medicine (TCM)."Kang edge pharmaceutical chairman XiaoWei think,Standardization is to enhance the safety of traditional Chinese medicine products/Effectiveness is the most effective means.Nearly two years,Traditional Chinese medicine injection adverse event occurred frequently,In fact fundamentally,Traditional Chinese medicine injection itself is not the problem,But Chinese medicine injection production process/In the process of raw materials and finished products quality control standard has a problem.

　　萧伟指出，标准化是传统中药走出国门，走向世界的关键所在。中药只有坚持标准化为方向，才能真正走向国际化。标准化也是现代中药发展的必然选择。以标准化为基础，才能进一步解析中药的物质基础、化学成分结构和靶点之间的对应关系。

XiaoWei pointed out that,Standardization is traditional Chinese medicine out of the country,The key to the world.Traditional Chinese medicine only adhere to the standard into direction,Can we truly toward internationalization.Standardization is the inevitable choice for the development of modern Chinese medicine.Based on standard into,To further analysis of the material basis of traditional Chinese medicine/Chemical composition structure and the corresponding relations between the target.

　　有学者认为，中药企业创新可采用病证组合模式，这是中药新药临床试验采用的基本模式。其次是探索建立支持创新、服务创新的管理新机制，坚持以临床需求为导向，以合理的价格对创新予以支持。再次是鼓励中药新剂型、新辅料的研究和产业化应用。(曾亮亮 朱旭东）

Some scholars think that,Traditional Chinese medicine enterprise innovation can use combination of disease and syndrome mode,This is Chinese herbal medicine new medicine clinical trials using basic pattern.The second is the possibility to support innovation/Service innovation management mechanism,Adhere to the clinical demand as the guide,At a reasonable price to support to innovation.Again is to encourage new dosage forms of traditional Chinese medicine (TCM)/New materials research and industrialization application.(Had ZhuXuDong thanked)